Clinical trial
PARPi or Capecitabine Combined With PD-1 Inhibitors Was Selected Based on the Germline BRCA1/2 Mutation vs. PD-1 Inhibitors Alone as Adjuvant Therapy in High-risk Non-pCR TNBC
NCT06533384 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PARPi or Capecitabine Combined With PD-1 Inhibitors Was Selected Based on the Germline BRCA1/2 Mutation vs. PD-1 Inhibitors Alone as Adjuvant Therapy in High-risk Non-pCR TNBC
- Lead sponsor
- Guangdong Provincial People's Hospital
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- August 1, 2024
- Completion date
- December 31, 2030
- Enrollment
- 310 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
triple-negative breast cancer